Literature DB >> 17342650

A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor.

James J Walsh1, Nicki Pesik, Conrad P Quinn, Veronica Urdaneta, Clare A Dykewicz, Anne E Boyer, Jeannette Guarner, Patricia Wilkins, Kim J Norville, John R Barr, Sherif R Zaki, Jean B Patel, Sarah P Reagan, James L Pirkle, Tracee A Treadwell, Nancy Rosenstein Messonnier, Lisa D Rotz, Richard F Meyer, David S Stephens.   

Abstract

This report describes the first case of naturally acquired inhalation anthrax in the United States since 1976. The patient's clinical course included adjunctive treatment with human anthrax immunoglobulin. Clinical correlation of serologic assays for the lethal factor component of lethal toxin and anti-protective antigen immunoglobulin G are also presented.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17342650     DOI： 10.1086/512372

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  49 in total

Review 1.  Anthrax lethal and edema toxins in anthrax pathogenesis.

Authors:  Shihui Liu; Mahtab Moayeri; Stephen H Leppla
Journal:  Trends Microbiol       Date:  2014-03-27       Impact factor: 17.079

2.  Detection of anthrax protective antigen (PA) using europium labeled anti-PA monoclonal antibody and time-resolved fluorescence.

Authors:  Robyn A Stoddard; Conrad P Quinn; Jarad M Schiffer; Anne E Boyer; Jason Goldstein; Dennis A Bagarozzi; Stephen D Soroka; Leslie A Dauphin; Alex R Hoffmaster
Journal:  J Immunol Methods       Date:  2014-05-22       Impact factor: 2.303

3.  Bacillus anthracis lethal toxin, but not edema toxin, increases pulmonary artery pressure and permeability in isolated perfused rat lungs.

Authors:  Xizhong Cui; Wanying Xu; Pranita Neupane; Andie Weiser-Schlesinger; Ray Weng; Benjamin Pockros; Yan Li; Mahtab Moayeri; Stephen H Leppla; Yvonne Fitz; Peter Q Eichacker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-15       Impact factor: 4.733

Review 4.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

Review 5.  Antitoxin Treatment of Inhalation Anthrax: A Systematic Review.

Authors:  Eileen Huang; Satish K Pillai; William A Bower; Katherine A Hendricks; Julie T Guarnizo; Jamechia D Hoyle; Susan E Gorman; Anne E Boyer; Conrad P Quinn; Dana Meaney-Delman
Journal:  Health Secur       Date:  2015 Nov-Dec

6.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

7.  Modulation of the Bacillus anthracis secretome by the immune inhibitor A1 protease.

Authors:  Kathryn J Pflughoeft; Michelle C Swick; David A Engler; Hye-Jeong Yeo; Theresa M Koehler
Journal:  J Bacteriol       Date:  2013-11-08       Impact factor: 3.490

8.  B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model.

Authors:  Yan Li; Xizhong Cui; Steven B Solomon; Kenneth Remy; Yvonne Fitz; Peter Q Eichacker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

9.  Quantification of the adenylate cyclase toxin of Bordetella pertussis in vitro and during respiratory infection.

Authors:  Joshua C Eby; Mary C Gray; Jason M Warfel; Christopher D Paddock; Tara F Jones; Shandra R Day; James Bowden; Melinda D Poulter; Gina M Donato; Tod J Merkel; Erik L Hewlett
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

10.  Anthrax lethal toxin enhances IkappaB kinase activation and differentially regulates pro-inflammatory genes in human endothelium.

Authors:  Jason M Warfel; Felice D'Agnillo
Journal:  J Biol Chem       Date:  2009-07-20       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.